Corporate News

Payment received

11 July 2022

Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Health & Nutrition and Global Health products, announces that it has received payment from Abingdon Health plc (“Abingdon”) in relation to the manufacture and supply of AbC-19™ Rapid tests, a COVID-19 lateral flow antibody test.

The payment was due under the Supply of Goods contract announced on 19 October 2020, and was made following confirmation from Abingdon that a cash payment had been received from the Department for Health & Social Care (“DHSC”) on 7 July 2022, as part of a settlement agreement relating to outstanding invoices due from DHSC to Abingdon. 

Contacts:  

Omega Diagnostics Group PLC  www.omegadx.com
Jag Grewal Chief Executive Officervia Walbrook PR
Chris Lea, Chief Financial Officer  
  
finnCap LtdTel: 020 7220 0500
Geoff Nash/Edward Whiley/George Dollemore (Corporate Finance)  
Alice Lane/ Harriet Ward (ECM)  
  
Walbrook PR Limited Tel: 020 7933 8780 or [email protected]
Paul McManus Mob: 07980 541 893
Lianne Applegarth Mob: 07584 391 303
Sam Allen Mob: 07502 558 258

 

About Omega Diagnostics Group PLC

Omega manufactures and distributes high quality in-vitro diagnostic products for use in hospitals, clinics, laboratories and healthcare practitioners in over 70 countries and specialise in the areas of health and nutrition and global health. www.omegadx.com 

Sign up for Investor Alerts